Learn more about how CAR-T may benefit your unique condition.
Call (405) 271-4022
CAR T-cell (chimeric antigen receptor T-cell) therapy is a form of immunotherapy that enhances the patient’s immune system to attack cancer cells more effectively. This therapy can be an option for adults with lymphoma that hasn’t responded to traditional chemotherapy, as well as for children and young adults with acute lymphoblastic leukemia.
In the immune system, T-cells are responsible for destroying abnormal or infected cells, including viruses and cancer.
Patients benefit OU Health being home to the state’s only CAR-T therapy program.
OU Health is home to the state’s only CAR-T therapy program. CAR-T is a specialized form of immunotherapy that uses genetically engineered T-cells to enhance the ability of a patient’s immune system to attack cancer cells. There is a possibility of it being found in adults with the following types of cancers:
However, in some patients, T-cells may not detect or destroy cancer cells effectively, or there may not be enough T-cells. CAR T-cell therapy involves genetically modifying T-cells to improve their ability to detect, target, and destroy cancer cells.
Our cancer specialists assess each patient to determine their eligibility for CAR T-cell therapy. After determining eligibility, this comprehensive treatment process takes a few weeks and involves the following steps:
Initially, the patient’s blood is processed through a specialized machine that extracts T-cells and returns the blood to the body. This procedure is painless and similar to donating blood, though it takes several hours to complete.
In a specialized laboratory, the T-cells are genetically altered using a disarmed virus. During this period, you will stay in the hospital, typically for several weeks. The T-cells are modified to recognize cancer cells and then multiplied to effectively combat the disease. These modified T-cells, now equipped with chimeric antigen receptors (CARs), are cultured to multiply into millions. This step can take several weeks.
The patient undergoes a short course of chemotherapy to reduce certain immune cells that might interfere with the new T-cells. To help improve the function of the cells, a lymphodepleting chemotherapy treatment is given to the patient before the CAR-T infusion.
The modified cells are infused into the body under the monitoring of the CAR-T care team on an outpatient basis. After the infusion, our CARt team will closely monitor you for side effects and ensure your condition is stable before you are discharged to go home.
Once infused, the genetically modified T-cells continue to multiply and circulate throughout the patient’s bloodstream, enhancing the body’s ability to target and attack cancer cells.
After receiving the CAR T-cell infusion, patients are required to stay near the hospital for at least four weeks. Depending on the type of cancer, the patient’s condition, and the specific treatment plan, this period may involve outpatient care or a combination of inpatient and outpatient care. It is essential for all patients to have a caregiver with them at all times to assist with care and monitor for any side effects.
Learn more about how CAR-T may benefit your unique condition.
Call (405) 271-4022As part of your Stephenson Cancer Center experience, you’ll partner with our dedicated, knowledgeable hematology nurse navigator who coordinates all aspects of your care. You and your caregivers can count on your navigator to serve as the best resource for helpful information, guidance and scheduling assistance throughout your journey.
Your choice to get care at OU Health Stephenson Cancer Center means you benefit from expertise you won’t find at other cancer centers in the state or region. You’ll work with experienced physicians who hold significant training in malignant hematology, cellular therapy and transplantation, as well as an expert hematopathologist onsite for quick evaluation of test results, specially trained nurses devoted to your care and a wide range of health professionals from multiple disciplines who apply their knowledge to your specific situation.
At OU Health, you have access to the latest CAR T-cell therapy clinical trials for a variety of cancers. These trials include additional subtypes of leukemia and lymphoma, multiple myeloma, and solid tumors such as breast cancer, lung cancer, pancreatic cancer, and prostate cancer.
Choosing Stephenson Cancer Center means you benefit from expertise you won’t find at other cancer centers in the state or region. You’ll work with experienced physicians who hold significant training in malignant hematology, transplant and cellular therapy. Benefits also include an onsite expert hematopathologist for quick evaluation of test results, specially trained nurses devoted to your care and a wide range of health professionals from multiple disciplines who apply their knowledge to your individual condition and dedicated to your care.
Join us for a cellular therapy and bone marrow transplant support group where we create a community ...
View Event DetailsIt is estimated that 40-90% of patients with cancer experience pain, and managing pain with cancer is ...
View Event DetailsWe are stronger together! Join us for in-person support groups where we discuss treatment, the social ...
View Event DetailsWe offer an in-person Chemo 101 class two times per month. This class is offered the first Thursday of ...
View Event DetailsJoin OU Health Stephenson Cancer Center from 9 a.m. to 3 p.m., Saturday, Nov. 9, for a lung cancer ...
View Event DetailsJoin us for a thought-provoking panel about prostate cancer, survivorship and community engagement on ...
View Event DetailsJoin us for the Hope in Oklahoma — Gynecologic Cancers Support Group where we discuss treatment, the ...
View Event DetailsLast Thursday of the month, 6 p.m.- 7 p.m. Living Room Lobby, Stephenson Cancer Center Contact: Mike ...
View Event DetailsLast Friday of the month, 5 - 6:30 p.m. Conference Room 5058, Stephenson Cancer Center Contact: Carmen ...
View Event DetailsDrug Shows Promise in Treating Mouth Sores Caused by Radiation, Chemotherapy OU Health Stephenson Cancer Center at the University of Oklahoma Health ...
Abdul Rafeh Naqash, M.D., a hematologist-oncologist with OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, has ...
Three faculty members have joined the TSET Health Promotion Research Center at the University of Oklahoma Health Sciences Center: Katelyn Romm, Ph.D.; ...